Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2009

01-12-2009 | Short communication

Foundation clinical trials

Author: David Cameron

Published in: Breast Cancer Research | Special Issue 3/2009

Login to get access

Excerpt

The present talk will address the following questions, posed as part of the 2009 Breast Cancer Controversies Meeting: Are clinical trials still essential to develop the new generation of biological agents? Are the traditional large clinical trials appropriate in developing drugs that may have a target in a minority of breast cancers? Are clinical trials compatible with the aim of individualising treatments? …
Literature
1.
Olivotto IA, Bajdik CD, Plenderleith IH, Coppin CM, Gelmon KA, Jackson SM, Ragaz J, Wilson KS, Worth A: Adjuvant systemic therapy and survival after breast cancer [see comment]. N Engl J Med. 1994, 330: 805-810. 10.1056/NEJM199403243301201.CrossRefPubMed
2.
Andre F, Slimane K, Bachelot T, Dunant T, Namer M, Barrelier A, Kabbaj O, Spano J-P, Marsiglia H, Rouzier R, Delalogue S, Spielman M: Breast cancer with synchronous metastases: trends in survival during a 14 year period. J Clin Oncol. 2004, 22: 3302-3308. 10.1200/JCO.2004.08.095.CrossRefPubMed
3.
Allred DC, Harvey JM, Berardo MD, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998, 11: 155-168.PubMed
4.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 [see comment]. N Engl J Med. 2001, 344: 783-792. 10.1056/NEJM200103153441101.CrossRefPubMed
5.
Smith IE: Efficacy and safety of Herceptin in women with metastatic breast cancer: results from pivotal clinical studies. Anti-Cancer Drugs. 2001, 12 (Suppl 4): S3-S10.CrossRefPubMed
6.
Thomlinson RH: Measurement and management of carcinoma of the breast. Clin Radiol. 1982, 33: 481-493. 10.1016/S0009-9260(82)80153-0.CrossRefPubMed
Metadata
Title
Foundation clinical trials
Author
David Cameron
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 3/2009
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2442

Other articles of this Special Issue 3/2009

Breast Cancer Research 3/2009 Go to the issue

Section introduction

Debate: tailored targeted therapy for all - a realistic and worthwhile objective? Introduction to Session 2

Short communication

Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors

Short communication

Alcohol consumption and breast cancer risk

Short communication

Are current drug development programmes realising the full potential of new agents? The scenario

Section introduction

Risk factors. Introduction to Session 1

Introduction

Controversies in Breast Cancer 2009
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits